Forge Medical announces commercialisation agreement for VasoStat haemostasis device


Forge Medical, manufacturer of the VasoStat haemostasis device that is used for radial artery and dialysis access haemostasis, announced that the company has entered into a national commercialisation agreement for the device with National Medical Sales.

Timothy WI Clark, cofounder and CEO of Forge Medical, said: “Transradial interventions are now commonly performed by interventional cardiologists, interventional radiologists, and vascular surgeons. As radial access continues to be rapidly adopted by endovascular physicians, clinicians demand an effective solution for puncture-site management with patent haemostasis. With the increasing data supporting the safety and superiority of transradial access over traditional transfemoral access, we are proud to provide a unique and innovative haemostasis device to meet this need.”

Clark is associate professor of Clinical Radiology at the University of Pennsylvania Perelman School of Medicine, Division of Interventional Radiology, Department of Radiology, and is the director of Interventional Radiology at Penn Presbyterian Medical Center in Philadelphia, USA.

Forge Medical will be exhibiting VasoStat at the 2015 TransRadial Endovascular Advanced Therapies in New York, USA, on 24 April 2015. The symposium is sponsored by the Icahn School of Medicine at Mount Sinai and will be held at the Leon and Norma Hess Center for Science and Medicine in New York, USA.

“We are excited to participate in the TREAT Symposium, the first of its kind geared toward interventional radiology and vascular surgery,” Clark said.